Another setback for Opdualag's post-melanoma plan
The latest failure, in colorectal cancer, follows a recent disappointment in second-line liver.
ASH 2023 preview – Darzalex gets a first-line boost from Perseus
But, with the end in sight for the CD38 blockbuster, will Johnson & Johnson buy into Genmab’s next-gen project?
